MicroPort Medbot
MicroPort Medbot (HKEX: 02252.HK) is a Shanghai-based surgical robotics subsidiary of MicroPort Scientific Corporation that develops and commercializes Toumai laparoscopic, SkyWalker orthopedic, R-One vascular, and bronchoscopic robotic systems across 60+ countries, serving tertiary hospitals and academic medical centers globally.
- Company typePublic
- Founded2014
- HeadquartersShanghai, China
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What MicroPort Medbot does
MicroPort Medbot (Shanghai Microport Medbot (Group) Co., Ltd., HKEX: 02252.HK) is a Shanghai-headquartered surgical robotics company and subsidiary of MicroPort Scientific Corporation (00853.HK), founded as an internal MicroPort project in 2014 and spun out as a standalone entity in 2015. The company designs, manufactures, and commercializes a portfolio of surgical robotic systems targeting laparoscopic, orthopedic, vascular interventional, bronchoscopic, and percutaneous biopsy procedures, with regulatory approvals spanning NMPA (China), FDA (US), CE (EU), ANVISA (Brazil), TGA (Australia), MHLW (Japan), MHRA (UK), and CDSCO (India). Its core products include the Toumai multi-port and single-port laparoscopic robots, the SkyWalker orthopedic robot (TKA/THA), the DFVision 3D fluorescence endoscope, the R-One vascular intervention robot, the Mona Lisa prostate biopsy robot, and the Trans-bronchial Surgical Robot (Dudao); supporting infrastructure includes the Neuron remote surgery network covering 30+ hospitals across 30 cities in China. Technology differentiators include the world's first regulatory-approved full-spectrum remote surgical platform, 5G/LEO satellite-enabled telesurgery over distances exceeding 10,000 km, the Neuron AI model capable of 88% autonomous procedure completion in preclinical trials, and proprietary lightweight robotic arms with 97% domestic components.
MicroPort Medbot firmographics
Firmographics- Name
- MicroPort Medbot
- Legal name
- Shanghai Microport Medbot (Group) Co., Ltd.
- Website
- https://medbotsurgical.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- MicroPort Medbot (HKEX: 02252.HK) is a Shanghai-based surgical robotics subsidiary of MicroPort Scientific Corporation that develops and commercializes Toumai laparoscopic, SkyWalker orthopedic, R-One vascular, and bronchoscopic robotic systems across 60+ countries, serving tertiary hospitals and academic medical centers globally.
- Ownership category
- akta.pro rank
MicroPort Medbot industry classification
Industry- Product category
- Surgical Robotics Systems
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
- akta.pro secondary industries
- Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL), Healthcare & Assistive Robotics (HDAAAIAC), Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)
Keywords
Where MicroPort Medbot is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
MicroPort Medbot business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Surgical Robot Systems Sales: Sale of surgical robotic systems including Toumai laparoscopic robot, SkyWalker orthopedic robot, and related equipment to hospitals and medical institutions globally. Revenue generated from system installations, with commercial deployment across 40+ countries
- Consumables and Accessories: Ongoing sales of surgical instruments, replacement parts, and consumables for installed robotic systems. Products include specialized instruments for different surgical procedures
- Training and Service Revenue: Revenue from training programs, installation services, maintenance contracts, and technical support associated with robotic systems. Includes partnership training centers like IRCAD collaboration
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
MicroPort Medbot product offering
Product offeringCore offering
MicroPort Medbot develops and manufactures intelligent surgical robotics systems including multi-port and single-port laparoscopic robots (Toumai), orthopedic surgical robots (SkyWalker), vascular intervention robots (R-One), 3D electronic laparoscopes (DFVision), prostate biopsy robots (Mona Lisa), and trans-bronchial surgical robots. The company sells these robotic systems along with AI-enabled software, remote surgery platforms, consumables, and training services to hospitals and medical institutions worldwide.
Product overview
MicroPort MedBot is a comprehensive surgical robotics portfolio offering end-to-end intelligent surgical solutions across five major procedural categories: laparoscopic (Toumai®), orthopedic (SkyWalker®), vascular intervention (R-One®), transbronchial, and percutaneous procedures. The product family includes multi-port and single-port laparoscopic robots, 3D fluorescence imaging systems (DFVision®), orthopedic joint replacement robots, vascular intervention robots, prostate biopsy robots, and bronchoscopy robots. The portfolio is unified through shared AI-enabled automation capabilities (Neuron AI), remote surgery infrastructure (Toumai® Remote System), and a proprietary Neuron® telesurgery network spanning 30+ cities. Key differentiators include industry-leading remote surgery capability via 5G/satellite connectivity and autonomous surgical features. The company operates as a subsidiary of MicroPort Scientific Corporation (00853.HK) and is listed on Hong Kong Stock Exchange (02252.HK).
Differentiator
Problem solved
Functional benefit
Brands
- Toumai®: Multi-port laparoscopic surgical robot for urology, general surgery, thoracic, gynecological and pediatric surgeries
- SkyWalker™ / 鸿鹄®
- DFVision® / 蜻蜓眼®
- R-One®
- Mona Lisa / 慧鱼®
Products and services
- Toumai® Laparoscopic Surgical Robot (图迈®腔镜手术机器人) A fully China-independently-developed multi-port laparoscopic surgical robot with 3D visualization, intuitive master-slave teleoperation, and highly flexible instruments for urological, general, thoracic, gynecological and pediatric surgeries. Features industry-leading remote surgery capability via 5G, satellite, and broadband networks.
- SkyWalker® Orthopedic Surgical Robot (鸿鹄®骨科手术机器人) First and only Chinese surgical robot certified by NMPA, FDA, CE, ANVISA, TGA, and MHLW, designed for total knee arthroplasty (TKA) and total hip arthroplasty (THA) with AI-based preoperative planning, precise bone cutting, and reduced surgical errors to ±0.5°.
- DFVision® 3D Fluorescence Endoscope (蜻蜓眼®DFVision®三维电子腹腔内窥镜) Core imaging component of the Toumai® surgical robot featuring multimodal fluorescence with eight modes, using indocyanine green (ICG) contrast agent for real-time visualization of tissue function, blood perfusion, and tumor margins during surgery.
- R-One® Vascular Intervention Robot (R-One®血管介入手术机器人) Coronary and peripheral vascular intervention robot enabling precise remote catheter manipulation, reducing X-ray exposure for medical staff while maintaining accuracy in complex vascular procedures.
- Mona Lisa Prostate Biopsy Robot (Mona Lisa前列腺穿刺机器人定位系统) Multi-disciplinary robot-assisted transperineal prostate biopsy system combining robot technology for minimally invasive, accurate, stable, and safe prostate biopsy procedures under transrectal ultrasound guidance.
- Trans-bronchial Surgical Robot (经支气管手术机器人) Bronchoscopy robot designed to reach targeted lung lesions through natural airways using flexible robotics with autopilot navigation capability.
- ANT (Automated Needle Targeting Robotics Systems) Percutaneous biopsy robot that analyzes X-ray or CT images, generates models, and automatically calculates puncture paths through AI algorithms for accurate biopsies in lung and kidney procedures.
- Toumai® Single-Port Laparoscopic Surgical Robot Single-incision laparoscopic surgical robot with dual C-arm architecture and high-flexibility snake-like instruments enabling precision in tight spaces and wide-range multi-quadrant operations.
Quantifiable outcome
- Surgery time reduced by approximately 50%
- +6 more outcomes
Companies that use MicroPort Medbot
Customer profileNamed customers17 records
Segments6 records
Ideal customer profiles3 records
MicroPort Medbot technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability11 records
Feature10 records
MicroPort Medbot partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- IRCAD (Institute of Research against Digestive Cancer)flagshipJointly inaugurated Toumai Robotics Training Center in Strasbourg, France at SRS2025 conference. IRCAD founder Prof. Jacques Marescaux (pioneer of remote surgery's 2001 Lindbergh Operation) participated, symbolizing fusion of historic and future remote surgery innovation. Center serves as platform for global training, academic collaboration, and clinical research.
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong UniversitycoreFive-year industry-university-research partnership for SkyWalker orthopedic robot development, producing first domestically developed surgical robot with certifications across major markets.
- ORSI (Belgium)coreEuropean training and academic partnership supporting robotic surgery adoption in Europe.
- Robocath (France)coreStrategic partnership established in 2020 for R-One vascular intervention robot development and中国市场 distribution.
- National Healthcare Security Administration (China)flagshipGovernment body that issued nationwide pricing guidelines for surgical robot auxiliary operations, establishing standardized national pricing tiers for remote surgery assistance fees, directly benefiting MicroPort MedBot's commercialization efforts.
- Thailand Ministry of HealthcoreNational collaboration driving adoption of Toumai through designated training center at Rajavithi Hospital.
Scale indicators17 records
Recent moves7 records
Expansion highlights6 records
MicroPort Medbot competitors and assessment
Company assessmentBroad incumbents
- Stryker: Maker of the Mako robotic system for orthopedic joint replacement (TKA/THA). Direct peer to SkyWalker in robotic-assisted knee and hip arthroplasty, with established global installed base and FDA/NICE-cleared systems competing for the same hospital budgets.
- Intuitive Surgical: Global leader in surgical robotics with the da Vinci platform—the dominant multi-port laparoscopic surgical robot. Directly comparable to Toumai in soft-tissue surgical applications with thousands of installed systems worldwide and the gold-standard incumbent that MedBot competes against globally.
- Medtronic: Developer of the Hugo robotic-assisted surgery system for soft-tissue procedures. Major medtech incumbent entering surgical robotics as a direct competitor to Toumai in laparoscopic applications, leveraging its global hospital sales infrastructure.
- Johnson & Johnson (Ethicon): Developer of the Ottava robotic surgical platform (in development/launch phase). Major medtech incumbent competing in soft-tissue surgical robotics with deep R&D resources and hospital relationships overlapping MedBot's target market.
Direct peers
- Robocath: French developer of the R-One vascular intervention robot—actually a MicroPort partner for the China market. Direct peer in robotic-assisted percutaneous coronary intervention, addressing the same clinical use case as MedBot's R-One platform.
- THINK Surgical: Developer of the TSolution One robotic system for orthopedic joint replacement. Comparable to SkyWalker in TKA/THA applications with established FDA clearance and similar target hospital segment of orthopedic specialty centers.
- Smith+Nephew: Maker of the CORI handheld robotic-assisted orthopedic surgery system. Direct competitor to SkyWalker in joint replacement robotics, targeting similar ambulatory surgery centers and orthopedic specialty hospitals.
- TINAVI Medical Technologies: Chinese surgical robotics competitor and direct peer in both orthopedic and laparoscopic segments. TINAVI's Tianji robot competes with SkyWalker in orthopedics domestically, making it the closest head-to-head competitor in the Chinese market.
Emerging players
- Vicarious Surgical: Emerging developer of a single-port robotic surgical system with virtual reality interface. Comparable to MedBot's newly approved Toumai Single-Port system in addressing the single-incision surgical robotics category with similar miniaturization ambitions.
- Edge Medical Robotics: Chinese surgical robotics startup developing laparoscopic and orthopedic robotic systems. Emerging direct competitor in the same Chinese market segment, pursuing similar minimally invasive surgical robotics applications as MedBot.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks7 records
Key highlights8 records
Customer concentration
MicroPort Medbot social profiles
Digital presenceMicroPort Medbot compliance and trust
Trust signalCompliance7 records
MicroPort Medbot financial estimates
Financial estimateRevenue estimate
Valuation estimate
MicroPort Medbot leadership team
Management profileNumber of profiles
Profiles14 records
MicroPort Medbot subsidiaries and ownership
Company hierarchySubsidiaries4 records
MicroPort Medbot funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MicroPort Medbot M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MicroPort Medbot
What does MicroPort Medbot do?
MicroPort Medbot develops and manufactures intelligent surgical robotics systems including multi-port and single-port laparoscopic robots (Toumai), orthopedic surgical robots (SkyWalker), vascular intervention robots (R-One), 3D electronic laparoscopes (DFVision), prostate biopsy robots (Mona Lisa), and trans-bronchial surgical robots. The company sells these robotic systems along with AI-enabled software, remote surgery platforms, consumables, and training services to hospitals and medical institutions worldwide.
Is MicroPort Medbot a public or private company?
MicroPort Medbot is a public company. It is classified as public and is currently operating.
When was MicroPort Medbot founded?
MicroPort Medbot was founded in 2014. It employs 501 to 1,000 people.
Where is MicroPort Medbot based?
MicroPort Medbot is headquartered in Shanghai, China, in the Asia region.
How does MicroPort Medbot make money?
Three revenue lines are on record. Surgical Robot Systems Sales are the primary driver. The others are consumables and Accessories and training and Service Revenue.
Who are MicroPort Medbot's main competitors?
Broad incumbents on record are Stryker, Intuitive Surgical, Medtronic and Johnson & Johnson (Ethicon). Direct peers are Robocath, THINK Surgical, Smith+Nephew and TINAVI Medical Technologies. Emerging players are Vicarious Surgical and Edge Medical Robotics.
Does MicroPort Medbot have an API?
No public API is recorded for MicroPort Medbot.
What industry is MicroPort Medbot in?
MicroPort Medbot's product category is Surgical Robotics Systems. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHAEAL, Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine). Its NAICS code is 339112 and its SIC code is 3841.